Last reviewed 2026-04-19 · How we verify

flu matrix peptide p58-66

Baylor Health Care System · Phase 1 active Biologic

flu matrix peptide p58-66 is a Biologic drug developed by Baylor Health Care System. It is currently in Phase 1 development.

At a glance

Generic name	flu matrix peptide p58-66
Sponsor	Baylor Health Care System
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

flu matrix peptide p58-66 CI brief — competitive landscape report
flu matrix peptide p58-66 updates RSS · CI watch RSS
Baylor Health Care System portfolio CI

Frequently asked questions about flu matrix peptide p58-66

What is flu matrix peptide p58-66?

flu matrix peptide p58-66 is a Biologic drug developed by Baylor Health Care System.

Who makes flu matrix peptide p58-66?

flu matrix peptide p58-66 is developed by Baylor Health Care System (see full Baylor Health Care System pipeline at /company/baylor-health-care-system).

What development phase is flu matrix peptide p58-66 in?

flu matrix peptide p58-66 is in Phase 1.

Manufacturer: Baylor Health Care System — full pipeline
Compare: flu matrix peptide p58-66 vs similar drugs
Pricing: flu matrix peptide p58-66 cost, discount & access